CER Daily Newsfeed

Doctors Push HHS to Show More Change on Prior Authorizations

(6/11, Ganny Belloni, Bloomberg Law) reports “...Nearly 4 out of 5 physicians surveyed by the AMA in 2025 reported patients abandoning treatment because of the prior authorization process, and over a quarter reported care delays that led to serious hospitalizations or even death. Only about a third of doctors surveyed by the AMA believed that insurers’ pledges would make a meaningful difference. ‘We believe that prior authorization processes desperately need meaningful reform,’ said ACP President Jan Carney. ‘We recommend that the administration continue to have real collaborations with physicians, clinicians, and patient advocacy groups.’” Subscription Required

First EU Joint Clinical Assessment Report Exposes Challenges in Generating Comparative Evidence

(6/11, Joanne Walker, Katie McCool, The Evidence Base) reports “...Professor Olaf Witt, Director of Translational Pediatric Oncology at the Hopp Children’s Cancer Center Heidelberg, described the constraints associated with evidence generation in this setting: ‘Randomized comparative studies… are often unfeasible due to limited patient availability, while withholding potentially beneficial therapy raises ethical concerns. In this context, ensuring timely access to innovation without compromising scientific rigor is critical.’” Full

China Pharma Trends: Premium Pricing and Priority Access for True Innovations

(6/11, Bruce Liu, PharmExec) reports “...Across the pricing, access and reimbursement dimensions, RWE is becoming an increasingly important consideration in China. In fact, compelling real-world data and China-specific evidence were behind some of the notable successes of the NRDL and the C-List last year, and the role of RWE has been further underscored in the State Council guidance, in a set of guidelines issued by the National Healthcare Security Administration (NHSA) earlier this year, and in the latest NRDL 2026 guideline issued in May.” Full